Improving Lives Through Nuclear Medicine™

Jubilant Moments

Jubilant Moments

What is a Jubilant Moment?

A single special moment in time that defines the essence of who we are and what we do, along our journey to Improving Lives Through Nuclear Medicine.

  • The day industry came together to solidify the future of cardiac PET

    Jubilant Moment #15

    In the summer of 2019 the Centers for Medicare and Medicaid Services (CMS) published their proposed payments for Calendar 2020.  In the proposed rule for PFS payments they proposed significant reductions, as high as 80%, for office-based and free-standing center myocardial PET services. Understanding the negative impact this would have on patients across the country our Radiopharmaceuticals Division immediately began to work alongside other industry partners, medical societies and other advocacy groups to gather data in an effort to change the proposed payment reductions.

    It is our great pleasure to announce that CMS released the Final 2020 Medicare Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System Rules (HOPPS) and the proposed payment reduction for 2020 had been reversed by CMS for calendar 2020.   This is an important win for PET cardiology and the patients who would have been affected by the reduction in coverage.

     

  • The first day she woke up pain free

    Jubilant Moment #5

    In October 2019, we announced that our Radiopharmacies Division signed an exclusive distribution agreement with                Q BioMed for Strontium-89 Chloride (Sr-89), a product indicated for the relief of bone pain in patients with painful skeletal metastases.   Jubilant Moment #5 was the day we distributed the first dose of Sr-89 to a patient who relies on us.

    Our vision is to Improve Lives Through Nuclear Medicine, it is the cornerstone of everything we do and shipping this does and helping this patient, is why we do what we do.  Bone metastases, often cause deep and endless pain. Palliative options for the control of this pain include analgesic support, cytotoxic chemotherapy and external-beam radiotherapy.   Sr-89 is used to help provide the patient with relief from the bone pain.

    The radioactive strontium is taken up in the bone cancer area and emits beta radiation directly into the metastases with little or no side-effects as compared to other palliative treatment options. In clinical trials, 75% of the cancer patients with metastatic bone disease who received Sr-89 experienced a reduction in pain, with 25%-30% of patients reporting complete pain relief.  The impact on the quality of life for patients is immeasurable.

     

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.